Welcome to Debate Club! Please be aware that this is a space for respectful debate, and that your ideas will be challenged here. Please remember to critique the argument, not the author.
We are pleased to announce that on March 4, 2025, an updated Rich Text Editor will be introduced in the MyFitnessPal Community. To learn more about the upcoming changes, please click here. We look forward to sharing this new feature with you!

The GLP-1 juggernaut is slowing. Eli Lily missed a sales target.

MargaretYakoda
MargaretYakoda Posts: 2,995 Member
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-misses-third-quarter-profit-amid-soaring-demand-weight-loss-drug-2024-10-30/

Looks like there’s a limit to demand for GLP-1 meds.

Replies